Literature DB >> 23977545

Chemotherapy for malignant pleural mesothelioma: a review of current management and a look to the future.

Anna K Nowak1.   

Abstract

Entities:  

Year:  2012        PMID： 23977545      PMCID： PMC3741799          DOI： 10.3978/j.issn.2225-319X.2012.10.05

Source DB:  PubMed          Journal:  Ann Cardiothorac Surg        ISSN： 2225-319X


× No keyword cloud information.
  44 in total

1.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Authors:  Matthew Bott; Marie Brevet; Barry S Taylor; Shigeki Shimizu; Tatsuo Ito; Lu Wang; Jenette Creaney; Richard A Lake; Maureen F Zakowski; Boris Reva; Chris Sander; Robert Delsite; Simon Powell; Qin Zhou; Ronglai Shen; Adam Olshen; Valerie Rusch; Marc Ladanyi
Journal:  Nat Genet       Date:  2011-06-05       Impact factor: 38.330

2.  A phase II study of sorafenib in malignant mesothelioma: results of Cancer and Leukemia Group B 30307.

Authors:  Sarita Dubey; Pasi A Jänne; Lee Krug; Herbert Pang; Xiaofei Wang; Robin Heinze; Colleen Watt; Jeff Crawford; Robert Kratzke; Everett Vokes; Hedy Lee Kindler
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

3.  Merlin/NF2 suppresses tumorigenesis by inhibiting the E3 ubiquitin ligase CRL4(DCAF1) in the nucleus.

Authors:  Wei Li; Liru You; Jonathan Cooper; Gaia Schiavon; Angela Pepe-Caprio; Lu Zhou; Ryohei Ishii; Marco Giovannini; C Oliver Hanemann; Stephen B Long; Hediye Erdjument-Bromage; Pengbo Zhou; Paul Tempst; Filippo G Giancotti
Journal:  Cell       Date:  2010-02-19       Impact factor: 41.582

4.  Single agent maintenance therapy for advanced stage non-small cell lung cancer: a meta-analysis.

Authors:  Madhusmita Behera; Taofeek K Owonikoko; Zhengjia Chen; Scott A Kono; Fadlo R Khuri; Chandra P Belani; Suresh S Ramalingam
Journal:  Lung Cancer       Date:  2012-04-28       Impact factor: 5.705

5.  A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.

Authors:  M E R O'Brien; D Watkins; C Ryan; K Priest; C Corbishley; A Norton; S Ashley; N Rowell; R Sayer
Journal:  Ann Oncol       Date:  2005-11-29       Impact factor: 32.976

6.  Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma.

Authors:  Paolo A Zucali; Giovanni L Ceresoli; Isabella Garassino; Fabio De Vincenzo; Raffaele Cavina; Elisabetta Campagnoli; Federico Cappuzzo; Silvia Salamina; Hector J Soto Parra; Armando Santoro
Journal:  Cancer       Date:  2008-04-01       Impact factor: 6.860

7.  Cediranib in patients with malignant mesothelioma: a phase II trial of the University of Chicago Phase II Consortium.

Authors:  Nicholas P Campbell; Rangesh Kunnavakkam; Natasha Leighl; Mark D Vincent; David R Gandara; Marianna Koczywas; Barbara J Gitlitz; Edem Agamah; Sachdev P Thomas; Walter M Stadler; Everett E Vokes; Hedy L Kindler
Journal:  Lung Cancer       Date:  2012-07-23       Impact factor: 5.705

8.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

9.  BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization.

Authors:  Karen H Ventii; Narra S Devi; Kenneth L Friedrich; Tatiana A Chernova; Mourad Tighiouart; Erwin G Van Meir; Keith D Wilkinson
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

10.  The role of folate receptor alpha (FRalpha) in the response of malignant pleural mesothelioma to pemetrexed-containing chemotherapy.

Authors:  J E Nutt; A R A Razak; K O'Toole; F Black; A E Quinn; A H Calvert; E R Plummer; J Lunec
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640
View more
  22 in total

1.  Efficacy of third-line pemetrexed monotherapy versus pemetrexed combination with bevacizumab in patients with advanced EGFR mutation-positive lung adenocarcinoma.

Authors:  Cheng-Zhi Zhou; Yin-Yin Qin; Zhan-Hong Xie; Jie-Xia Zhang; Ming Ou-Yang; Shi-Yue Li; Rong-Chang Chen
Journal:  Chin J Cancer Res       Date:  2014-12       Impact factor: 5.087

2.  Pleurectomy/decortication versus extrapleural pneumonectomy: a critical choice.

Authors:  Pier Luigi Filosso; Francesco Guerrera; Paolo Olivo Lausi; Roberto Giobbe; Paraskevas Lyberis; Enrico Ruffini; Alberto Oliaro
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

Review 3.  The role of interleukin-6 in malignant mesothelioma.

Authors:  Siti N Abdul Rahim; Gwo Y Ho; Jermaine I G Coward
Journal:  Transl Lung Cancer Res       Date:  2015-02

Review 4.  Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects.

Authors:  Lukasz Kuryk; Giulia Rodella; Monika Staniszewska; Katarzyna Wanda Pancer; Magdalena Wieczorek; Stefano Salmaso; Paolo Caliceti; Mariangela Garofalo
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

5.  Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions.

Authors:  Adam Szulkin; Rita Otvös; Carl-Olof Hillerdal; Aytekin Celep; Eviane Yousef-Fadhel; Henriette Skribek; Anders Hjerpe; László Székely; Katalin Dobra
Journal:  BMC Cancer       Date:  2014-09-24       Impact factor: 4.430

6.  Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma.

Authors:  Iris Chiara Salaroglio; Ivana Campia; Joanna Kopecka; Elena Gazzano; Sara Orecchia; Dario Ghigo; Chiara Riganti
Journal:  Oncotarget       Date:  2015-01-20

7.  Prolonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMT.

Authors:  Colin Charles Tièche; Ren-Wang Peng; Patrick Dorn; Laurène Froment; Ralph Alexander Schmid; Thomas Michael Marti
Journal:  BMC Cancer       Date:  2016-02-19       Impact factor: 4.430

8.  Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study).

Authors:  C Raynaud; L Greillier; J Mazieres; I Monnet; B Mastroianni; G Robinet; G Fraboulet; A Dixmier; H Berard; R Lamy; J Letreut; H Lena; G Oliviero; S Botta; A Vergnenegre; I Borget; C Chouaid
Journal:  BMC Cancer       Date:  2015-11-06       Impact factor: 4.430

9.  Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease.

Authors:  Barbara Nuvoli; Sabrina Germoni; Carlotta Morosetti; Raffaela Santoro; Giancarlo Cortese; Serena Masi; Iole Cordone; Rossella Galati
Journal:  Mol Cancer       Date:  2014-03-21       Impact factor: 27.401

Review 10.  Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of life-relation to chemotherapy, radiotherapy, and alternative therapies.

Authors:  Sotiris Papaspyros; Sayonara Papaspyros
Journal:  ISRN Surg       Date:  2014-02-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.